Pre-pregnancy counselling and optimisation

It is a Tuesday in the pre-pregnancy clinic. A 34-year-old with type 1 diabetes, on an ACE inhibitor, taking 400 micrograms of folate, asks whether she can start trying next month. Every one of those facts is a problem the counselling visit exists to fix — and if the visit happens after conception, three of them are already too late. Pre-pregnancy care is the one part of obstetrics where the registrar's job is to prevent the pathology rather than manage it.[1][5]

Overview and definition

Pre-pregnancy (preconception) counselling is the assessment and optimisation of a woman's health, lifestyle, medications and chronic disease before she conceives, with the explicit aim of reducing maternal and fetal harm. RANZCOG frames it as advice to "support the counselling of women prior to pregnancy." It runs on two tracks at once.[1]

• Universal (everyone): folate, iodine, no alcohol, no smoking, weight, immunisations, infection screening.[1][4]
• Targeted (the at-risk woman): diabetes, hypertension and cardiac disease, epilepsy, thyroid disease, obesity, renal disease, thrombophilia, prior adverse outcome, consanguinity.[1][5]

The driver underneath all of it is one uncomfortable number: in the US, around two-thirds of reproductive-aged women carry at least one modifiable risk factor for an adverse pregnancy outcome. That is why preconception care is delivered opportunistically — at contraception review, the six-week postnatal visit, and any well-woman contact — not only at a dedicated clinic.[2]

References14Show ledgerHide ledger

1. [1]Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) Pre-pregnancy counselling (C-Obs 3a), Version 13.1 RANZCOG Clinical Guideline, 2024.Source
2. [2]Cooper KM, Szymanski LM, David PS, et al. Prepregnancy Care and Counseling: A Review JAMA, 2026.PMID 42008245
3. [3]MRC Vitamin Study Research Group Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group Lancet, 1991.PMID 1677062
4. [4]Barry MJ, Nicholson WK, Silverstein M, et al. Folic Acid Supplementation to Prevent Neural Tube Defects: US Preventive Services Task Force Reaffirmation Recommendation Statement JAMA, 2023.PMID 37526713
5. [5]American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics ACOG Practice Bulletin No. 201: Pregestational Diabetes Mellitus Obstet Gynecol, 2018.PMID 30461693
6. [6]Meador KJ, Baker GA, Browning N, et al. Effects of fetal antiepileptic drug exposure: outcomes at age 4.5 years Neurology, 2012.PMID 22491865
7. [7]Christensen J, Grønborg TK, Sørensen MJ, et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism JAMA, 2013.PMID 23613074
8. [8]Adam MP, Polifka JE, Friedman JM Evolving knowledge of the teratogenicity of medications in human pregnancy Am J Med Genet C Semin Med Genet, 2011.PMID 21766440
9. [9]Murphy HR, Howgate C, O'Keefe J, et al. Characteristics and outcomes of pregnant women with type 1 or type 2 diabetes: a 5-year national population-based cohort study Lancet Diabetes Endocrinol, 2021.PMID 33516295
10. [10]Tsiapakidou S, Mahmood T, Savona-Ventura C The potential impact of tobacco use on female fertility and pregnancy outcomes: An invited scientific review by EBCOG Eur J Obstet Gynecol Reprod Biol, 2023.PMID 37741060
11. [11]Taylor PN, Okosieme OE, Dayan CM, et al. Therapy of endocrine disease: Impact of iodine supplementation in mild-to-moderate iodine deficiency: systematic review and meta-analysis Eur J Endocrinol, 2014.PMID 24088547
12. [12]Korevaar TIM, Leung AM, Alexander EK, et al. American Thyroid Association 2026 Guidelines for Thyroid Disease in Preconception, Pregnancy, and Postpartum Thyroid, 2026.PMID 42219800
13. [13]Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) Reproductive Carrier Screening (C-Obs 63), Interim RANZCOG Statement, 2024.Source
14. [14]Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) Substance use in pregnancy (C-Obs 53) RANZCOG Clinical Guideline, 2024.Source